Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Restaxil Nervenschmerzgel
- Development stage
- Unknown
- Lead developer
- PharmaSGP
- Administration
- Topical
01
Overview
Restaxil Nervenschmerzgel is a homeopathic topical gel developed by PharmaSGP and Restaxil for the treatment of pain and abnormal sensations (such as tingling, burning, or numbness) caused by nerve damage (neuropathic pain). It is formulated with a dual complex of two active homeopathic ingredients: *Spigelia anthelmia* (wormweed) and *Iris versicolor* (variegated iris), both diluted to D2. The gel is applied topically to the affected areas, such as the back, neck, legs, or feet, to provide localized relief. It is registered as an over-the-counter medicinal product (Arzneispezialität) in Austria.
- Brand names
- Restaxil Nervenschmerzgel
- Other names
- Restaxil Nerve Pain GelRestaxil Nervenschmerz Gel
Beyond the preview
Go deeper on Restaxil Nervenschmerzgel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Restaxil Nervenschmerzgel.